Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

The Quell 2.0 can’t assess or measure pain, so it needs you to do it, selecting from 0-10 the level of pain you felt generally, when active, while sleeping and how it affected your mood. Using those ...
Business Wire

NeuroMetrix’ Quell Device Makes Second Appearance at American Society of Regional Anesthesia’s Annual Pain Medicine Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell ® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American ...
MobiHealthNews

Neurometrix gets FDA clearance for smartphone-controlled Quell device

Neurometrix has received FDA clearance for a new smartphone-controlled version of Quell, its wearable for pain relief, the company announced last week. Like its predecessor, the device will use nerve ...
Business Insider

NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain

WALTHAM, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of results from a randomized controlled trial of Quell ® in subjects with chronic low back ...
Business Wire

NeuroMetrix to Sponsor Study Assessing the Impact of Quell Technology on Chronic Low Back Pain

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today announced a clinical study of Quell ® Wearable Pain Relief Technology™ in patients with chronic low back pain at the ...
CNN

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct ...
Business Insider

NeuroMetrix Reports Presentation of Clinical and Scientific Data on Quell Wearable Pain Relief Technology at PAINWeek 2018 National Conference

WALTHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference ...
Nasdaq

NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device

WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a ...